Acurx Pharmaceuticals (ACXP)
(Delayed Data from NSDQ)
$2.02 USD
-0.01 (-0.49%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $2.00 -0.02 (-0.99%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ACXP 2.02 -0.01(-0.49%)
Will ACXP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ACXP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for ACXP
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference
Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Tuesday's Intraday Session
Acurx files common stock offering, no amount given